EZETIMIBE 10mg. IP

The first agent of a novel class of selective cholesterol absorption inhibitors approved by the Food and Drug Administration, ezetimibe inhibits the absorption of biliary and dietary cholesterol from the small intestine without affecting the absorption of fat-soluble vitamins, triglycerides, or bile acids. (Patrick, 2002) Acts at the brush border of the small intestine by targeting the Niemann-Pick C1-like transporter, blocking the absorption of dietary and biliary cholesterol and plant sterols, resulting in intracellular cholesterol depletion. (Patrick, 2002) Reduces fractional cholesterol absorption by 54% compared to placebo, followed by clinically relevant reductions in LDL and total cholesterol concentrations. (Gagne, 2002) Reduces low-density lipoprotein cholesterol (LDL) by 15–20% while increasing high-density lipoprotein cholesterol by 2.5–5% when given as monotherapy or in combination with statins or fenofibrate. (Ballantyne, 2003) Demonstrated a 15.1% greater reduction in LDL-C when combined with statin therapy compared with statin alone, across a meta-analysis of 27 studies including more than 21,000 patients. (Obicetrapib Study, 2023) Results in incremental lowering of LDL cholesterol levels and improved cardiovascular outcomes when added to statin therapy. (Cannon, 2015) Has a favourable drug–drug interaction profile and can be administered in the morning or evening without regard to food. (Kosoglou, 2005)